A Transit Compartment Model Unmasks OxyContin's Reflective Pharmacokinetics From Urine Measurements in Humans

REFERENCES

• Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother. 2006;40:1327–1335.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Kaiko RF, Oshlack B. Characteriztion and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996;42:747–756.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Farrar JT, Backonja MM, Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287–299.
   PubMed Web of Science ®Google Scholar
• Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837–1841.
   PubMed Web of Science ®Google Scholar
• Rauck RL, Bookbinder SA, Bunker TR, A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. J Opioid Manag. 2007;3:35–43.
   PubMedGoogle Scholar
• Reder RF. Opioid formulations: tailoring to the needs in chronic pain. Eur J Pain. 2001;5(Suppl A):109–111.
   PubMed Web of Science ®Google Scholar
• Berner T, Thomson H, Hartry A, Puenpatom RA, Ben-Joseph R, Szeinbach SL. A comparison of daily average consumption of controlled release (OxyContin CR) and oxymorphone extended release (Opana ER) in patients with low back pain. Pharm Ther. 2011;36:139–144.
   Google Scholar
• Gammaitoni AR, Davis MW. Comparison of the pharmacokinetics of oxycodone administered in three percocet formulations. J Clin Pharmacol New Drugs. 2002;42:192–197.
   Google Scholar
• Kaiko RF, Benziger DP, Fitzmartin RD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharm Ther. 1996;59:52–61.
   PubMed Web of Science ®Google Scholar
• Reder RF, Oshlack B, Miotto J, Benziger DP, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996;18:95–105.
   PubMed Web of Science ®Google Scholar
• Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage. 1997;13:75–82.
   PubMed Web of Science ®Google Scholar
• Kaiko R. Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand. 1997;41:166–174.
   PubMed Web of Science ®Google Scholar
• Eliot L, Geiser R, Loewen G. Steady-state pharmacokinetic comparison of a new, once daily, extended-release morphine formulation (MorphelanTM) and OxyContin twice daily. J Oncol Pharm Pract. 2001;7:1–8.
   Google Scholar
• Pöyhia R, Seppala T, Olkkola K, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharm. 1992;33:617–621.
   PubMed Web of Science ®Google Scholar
• Linares OA, Linares AL. Computational opioid prescribing: a novel application of clinical pharmacokinetics. J Pain Palliat Care Pharmacother. 2011;25:125–135.
   PubMedGoogle Scholar
• Linares OA, Daly D, Stefanovski D, Boston RC. A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. J Pain Palliat Care Pharmacother. 2013;27:1–11.
   Google Scholar
• Linares OA, Jacquez J, Zech L, Norepinephrine metabolism in humans: kinetic analysis and model. J Clin Invest. 1987;80:1332–1341.
   PubMed Web of Science ®Google Scholar
• Cobelli C, Caumo A. Using what is accessible to measure that which is not: necessity of model of system. Metabolism. 1998;47:1009–1035.
   PubMed Web of Science ®Google Scholar
• Wastney M, Patterson B, Linares O, Greif P, Boston R. Investigating Biological Systems Using Modeling: Strategies and Software. San Diego: Academic Press; 1999.
   Google Scholar
• Jacquez J. Design of expermints. J Franklin Inst. 1998;335B:259–279.
   Google Scholar
• Cone EJ, Heltsley R, Black DL, Mitchell JM, LoDico CP, Flegel RR. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration. J Anal Toxicol. 2013;37:255–264.
   PubMed Web of Science ®Google Scholar
• Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol. 2008;19:1076–1078.
   PubMed Web of Science ®Google Scholar
• Mercandante S, Arcuri E. Opioids and renal function. J Pain. 2004;5:2–19.
   PubMed Web of Science ®Google Scholar
• Tucker J. Measurement of the renal clearance of drugs. Br J Clin Pharmacol. 1981;12:761–770.
   PubMed Web of Science ®Google Scholar
• Barnes JN, Williams AJ, Thomson MJF, Toesland PA, Goodwin FJ. Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. Br Med J. 1985;290:740–742.
   PubMed Web of Science ®Google Scholar
• Hansen PC. Rank-Deficient and Discrete Ill-Posed Problems. Philadelphia: Society for Industrial and Applied Mathematics; 1998.
   Google Scholar
• Boston RC, Moate PJ, Allison KC, Lundgren JD, Stunkard AJ. Modeling circadian rhythms of food intake by means of parametric deconvolution: results from studies of the night eating syndrome. Am J Clin Nutr. 2008;87:1672–1677.
   PubMed Web of Science ®Google Scholar
• Boston RC, Pei D, Moate PJ. A numerical deconvolution method to estimate C-peptide secretion in humans after an intravenous glucose tolerance test. Metabolism. 2009;58:891– 900.
   PubMed Web of Science ®Google Scholar
• Aster RC, Borchers B, Thurber CH. Parameter Estimation and Inverse Problems. Waltham, MA: Elsevier; 2013.
   Google Scholar
• Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64:603–611.
   PubMed Web of Science ®Google Scholar
• Lugo RA. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004;18:17–30.
   PubMedGoogle Scholar
• Linares OA, Daly DT, Stefanovski D, Boston RC. A new model for using quantitative urine testing as a diagnostic tool for oxycodone treatment and compliance. J Pain Palliat Care Pharmacother. 2013;27(3):244–254.
   PubMedGoogle Scholar
• Cruz RL. A calculus for network delay, part I: network elements in isolation. IEEE Trans Inform Theor. 1991;37:114– 131.
   Web of Science ®Google Scholar
• Cruz RL. A calculus for network delay, part II: network analysis. IEEE Trans Inform Theor. 1991;37:132–141.
   Web of Science ®Google Scholar
• Savic RM, Jonker DM, Kerbusch T, Karlsson M. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711–726.
   PubMed Web of Science ®Google Scholar
• Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev. 1996;19:359–376.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186:119–125.
   PubMed Web of Science ®Google Scholar
• Jacquez J, Greif P. Numerical parameter identifiability and estimability: integrating identifiability, estimability, and optimal sampling design. Math Biosci. 1985;77:201–227.
   Web of Science ®Google Scholar
• Stefanovski D, Moate P, Boston R. WINSAAM: a Windows-based compartmental modeling system. Metabolism. 2003;52:1153–1166.
   PubMed Web of Science ®Google Scholar
• Lyne A, Boston R, Pettigrew K, Zech L. EMSA: a SAAM service for the estimation of population parameters based on model fits to identically replicated experiments. Comput Methods Programs Biomed. 1992;38:117–151.
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P. Mean time parameters in pharmacokinetics. Definition, computation, and clinical implications (Part I). Clin Pharmacokinet. 1989;17:345–366.
   PubMed Web of Science ®Google Scholar
• Veng-Pedersen P. Mean time parameters in pharmacokinetics. Definition, computation and clinical pharmacokinetics (Part II). Clin Pharmacokinet. 1989;17:424–440.
   PubMed Web of Science ®Google Scholar
• Linares-Daly A. Opioid pseudoaddiction: a casualty of the war on drugs, racism, sexism, and opiophobia. Quinnipiac Health Law J. 2012;58:447–474.
   Google Scholar
• Porhomayon J, Leissner KB, El-Solh AA, Nader ND. Strategies in postoperative analgesia in the obese obstructive sleep apnea patient. Clin J Pain. 2013;29:998–1005.
   PubMed Web of Science ®Google Scholar
• Linares OA. Pharmacokinetics-based opioid prescribing: case report. Pain Pract. 2010;20:19–21.
   Google Scholar
• Narasimhan B, Peppas NA. Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier. J Pharm Sci. 1997;86:297–304.
   PubMed Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hofer C. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharm Ther. 2006;79:461–479.
   PubMed Web of Science ®Google Scholar
• Galetin A, Houston JB. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther. 2006;318: 1220–1229.
   PubMed Web of Science ®Google Scholar
• Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 2003;43:149–173.
   PubMed Web of Science ®Google Scholar
• Cussler EL. Diffusion: Mass Transfer in Fluid Systems. Cambridge, UK: Cambridge University Press; 1984.
   Google Scholar
• Fournier RL. Basic Transport Phenomena in Biomedical Enginering. 3rd ed. Boca Raton, FL: CRC Press; 2012.
   Google Scholar
• Cussler EL. Diffusion: Mass Transport in Fluid Systems. 3rd ed. New York: Cambridge University Press; 2009.
   Google Scholar
• Iwan M, Jarmolowska B, Bielikowicz K, Koystra E, Koystra H, Kaczmarski M. Transport of μ-opioid receptor agonists and antagonists peptides across Caco-2 monolayer. Peptides. 2008;29:1042–1047.
   PubMed Web of Science ®Google Scholar
• Anderson DT, Fritz KL, Muto JJ. Oxycontin: the concept of a “ghost pill” and the postmortem tissue distribution of oxycodone in 36 cases. J Anal Toxicol. 2002;26:448–459.
   PubMed Web of Science ®Google Scholar
• Kim SK. Small intestine transit time in the normal small bowel study. AJR Am J Roentgenol. 1968;104:522–524.
   PubMed Web of Science ®Google Scholar
• Chan LN. Opioid analgesics and the gastrointestinal tract. Pract Gastroenterol. 2008;65:37–50.
   Google Scholar
• Baselt RC, Stewart CB. Determination of oxycodone and a major metabolite in urine by electron-capture GLC. J Anal Toxicol. 1978;2:107–109.
   Web of Science ®Google Scholar
• Andreassen TN, Klepstad P, Davies A, Influences on the pharmacokinetics of oxycodone: a multicentre corss-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol. 2011;67:493–506.
   PubMed Web of Science ®Google Scholar
• Schiesser WE. Computational Transport Phenomena. Cambridge, UK: Cambridge University Press; 1997.
   Google Scholar
• Schiesser WE. The Numerical Method of Lines Integration of Partial Differential Equations. San Diego, CA: Academic Press; 1991.
   Google Scholar
• Muzic RF, Saidel GM. Distributed versus compartment models for PET receptor studies. IEEE Trans Med Imag. 2003;22:11–21.
   PubMed Web of Science ®Google Scholar